Skip to main content

You are using an old and unsupported browser. Most core functionality will not work. Please upgrade to a supported browser - Google Chrome

Medical Oncology Group of Australia Incorporated
Medical Oncology Group of Australia Incorporated
Home
MSD

MSD

Featured
26 Talavera Rd, Macquarie Park, NSW 2113

About MSD

TAKE THE 3D VIRTUAL STAND TOUR

 Visit the  MSD virtual stand to access news and updates from MSD.

MOGA EXHIBITOR PASSPORT COMPETITION: VISIT OUR 3D STAND (CLICK LINK BELOW) -TO FIND OUT WHICH INDICATION OUR NEWEST PBS LISTING FOR KEYTRUDA (Pembrolizumab) IS FOR. CODE = ANSWER

 
CLICK HERE TO ENTER THE 3D VIRTUAL MSD STAND 


ABOUT MSD

For 130 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.msdoncology.com.au.

The materials for KEYTRUDA® (pembrolizumab) contained in this virtual exhibition are intended for Healthcare Professionals only and are approved for use only in Australia. Before prescribing, refer to the approved product information, available at www.msdinfo.com.au/keytrudapi. Prescribing information may vary depending on local approval in each country. KEYTRUDA is not listed on the PBS for certain indications. PBS information can be viewed at www.pbs.com.au

Copyright © 2021 Merck & Co., Inc., Kenilworth, NJ, USA, and its affiliates. All rights reserved. 
Merck Sharp & Dohme (Australia) Pty Limited. Level 1 – Building A, 26 Talavera Road, Macquarie Park NSW 2113. 
AU-KEY-00959. First issued July 2021.


Resources

Visit the MSD 3D virtual tour for all the latest information !
Booklet detailing the current indications for use of KEYTRUDA in Australia. Contains PBS Codes and STREAMLINED Authority Codes for relevant indications.
Booklet for healthcare professionals to help manage immune-mediated adverse events